Trovagene Precision Cancer Monitoring (PCM) provides noninvasive and quantitative alternatives to biopsy and imaging for tracking specific oncogene mutations over time, with the flexibility of urine- and blood-based testing.
Validating the potential of liquid biopsies as a viable alternative to traditional screening methods for cancer, FierceDiagnostics selects Trovagene as one of five companies to watch in the space. Read More.
Next-generation sequencing has enabled advances in oncology, both in research and clinical settings, and now seeks acceptance for a wider range of applications. At the 2015 Personalized Medicine World Conference, Genetic Engineering News took a look at some of these applications. Trovagene’s CSO, Mark Erlander, provided perspective into the potential for the growth of the liquid biopsy space. Read More.
Liquid biopsies have shown great promise in detecting and monitoring cancer. One contender, Trovagene, tells Clinica why it believes it has the edge over other companies in the space. Read More.
The Wall Street Transcript spoke with Trovagene's CEO, Dr. Antonius Schuh, for its annual life sciences report. The interview provides an overview of Trovagene's business model, steps to commercialization and numerous collaborations and partnerships in process. The interview also reviews the company's key objectives for 2015, potential business risks, and the compelling investment opportunity that exists. Read More.
Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are characterized by a high frequency of BRAF V600E mutations, which may occur in approximately 50% of patients with these diseases, and which are responsive to treatment with BRAF inhibitors such as vemurafenib. Read More.